Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

Not Applicable

Recruiting

• Conditions: Weight Loss; Colorectal Cancer; Time Restricted Eating; Obesity

• Registration Number: NCT05114798
• Lead Sponsor: University of Illinois at Chicago

Brief Summary

Approximately 42% of American adults are obese, and this condition is strongly related to the development of colorectal cancer. Innovative lifestyle strategies to treat obesity and reduce colorectal cancer risk are critically needed. This research will demonstrate that time-restricted eating, a type of intermittent fasting, is an effective therapy to help obese individuals reduce and control their body weight and prevent the development of colorectal cancer.

Detailed Description

Approximately 42% of the U.S. adult population is obese and data suggests that persons with obesity are at a 30% greater risk of developing colorectal cancer (CRC). Therefore, efficacious approaches to preventing and treating obesity will have significant effects on CRC incidence in the U.S. Although calorie restriction through lifestyle intervention is the most common approach to treat obesity, clinically meaningful weight loss is difficult to achieve via this method due to low adherence with calorie monitoring, indicating a need for innovation. Time-restricted eating, a type of intermittent fasting, has been shown in animals to impart cancer protective effects including lower body weight, decreased systemic inflammation, and improved glucose metabolism. Time-restricted eating is where individuals are asked to consume all their food for the day within a specified time frame, and water fast for the remaining hours of the day. We recently performed two short-term (≤12-weeks) pilot studies of time-restricted eating to evaluate its safety and preliminary efficacy on body weight and chronic disease risk markers in adults with obesity. Our results show the intervention is a safe and acceptable approach to weight loss among obese adults. Moreover, time-restricted eating produced approximately 3% weight loss from baseline and reductions in systolic blood pressure, oxidative stress and insulin resistance. Although these pilot findings show promise for time-restricted eating as an effective tool for CRC risk reduction among obese individuals, these data still require confirmation by a well powered longer-term clinical trial. The present proposal aims to implement a 12-month (6-month intervention, 6-month maintenance) controlled, parallel arm trial among 255 obese adults (45-70 years old) who have had a colonoscopy. Subjects will be randomized to 1 of 3 groups: 1) 8-hour time-restricted eating (daily ad libitum food intake from 12pm - 8pm), 2) Calorie restriction (daily 25% calorie restriction), or 3) Control (daily ad libitum food intake, no meal timing restrictions) to compare the effects on: (1) Body weight, body composition, and intervention adherence; (2) Circulating metabolic, inflammation, and oxidative stress-related biomarkers; (3) Colonic mucosal gene expression profiles and mucosal inflammation, DNA damage and cellular growth; and (4) maintenance of benefits on body weight/composition and CRC markers.

Study Timeline

• Study First Submitted: 2021-09-29
• Study First Submitted QC: 2021-11-05
• Study First Posted: 2021-11-10
• Study Start: 2022-05-17
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-07
• Last Update Posted: 2025-07-09
• Primary Completion: 2026-12-31
• Study Completion: 2027-08-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 255

Inclusion Criteria

1. 45-70 years old,
2. BMI 30-49.99 kg/m2
3. Are up to date with CRC screening.

Exclusion Criteria

1. Have a history of renal disease, autoimmune disorders, immunodeficiency, malabsorptive disorder, significant gastrointestinal and hepatic disease, surgical change in gastrointestinal anatomy, severe ischemic heart disease, severe pulmonary disease, severe mental health disorder, eating disorder, or bariatric surgery;
2. Abuse alcohol (> 50 grams/day), illicit drugs (other than self-reported marijuana use), or use combustible tobacco;
3. Have controlled type 2 diabetes or undiagnosed uncontrolled diabetes based on hemoglobin A1c (HbA1c) > 9.0%;
4. Have a history of cancer treatment within the past 12 months, CRC, genetic predisposition to CRC (e.g., Lynch syndrome);
5. Have a baseline body weight > 450 lbs (weight limitation of the DXA);
6. Are on a weight loss diet or actively involved in a formal weight loss program (e.g., Weight Watchers);
7. Are not weight stable for 3 months prior to the study (weight gain or loss > 4 kg);
8. Are unable to keep a food diary for 7 consecutive days during screening;
9. Are night shift workers;
10. Are pregnant or trying to get pregnant;
11. Are taking drugs that influence study outcomes (weight loss medications);
12. Are non-English speaking
13. Are taking anticoagulant medications or medications with endoscopic risk
14. Are taking antivirals or immunosuppressant medications
15. Don't have regular access to an email address and computer/smartphone/tablet
16. Are currently following a diet that requires fasting on a weekly basis
17. Currently eat for less than 10 hours of the day (determined by asking participants what time they start and stop eating on a usual day)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Weight change (% kg)	Baseline to month 6	Body weight in kg

Secondary Outcome Measures

Name	Time	Method
Intervention adherence	Monthly, through month 6	Measured through electronic diet records and 24 hour dietary recalls
Fasting plasma glucose	Baseline, month 3, month 6, month 9, month 12	From fasting venous blood measured by a commercial lab
CD3, CD163, pIKKa/b, tissue markers of inflammation	Baseline, month 6, month 12	Healthy colonic mucosa, immunohistochemistry
Colonic mucosa gene expression profiling	Baseline, month 6, month 12	Commercially available targeted transcriptomics platform
Weight maintenance (% kg)	Month 6 to month 12	Maintenance of weight loss
Fecal Metabolites	Baseline, month 3 and month 6	Untargeted Metabolomics
c-caspase-3, Bax, apoptosis	Baseline, month 6, month 12	Healthy colonic mucosa, immunohistochemistry,
Total and regional body fat composition and distribution	Baseline, 6 month and 12 month	Total and regional body fat composition and distribution will be measured via whole body DEXA scan
Plasma cytokines TNF-α, IL-6, IL1-β, and IL-10, %	Baseline, month 3, month 6, month 9, month 12	Multiplex ELISA
Plasma 8-isoprostane	Baseline, month 3, month 6, month 9, month 12	ELISA
Ki-67, proliferation	Baseline, month 6, month 12	Healthy colonic mucosa, immunohistochemistry
Fasting plasma insulin	Baseline, month 3, month 6, month 9, month 12	From fasting venous blood measured at a commercial lab
HOMA-IR	Baseline, month 3, month 6, month 9, month 12	calculated from fasting glucose and insulin using a standard formula
Gut Microbiome	Baseline, month 3 and month 6	Shotgun metagenomics
Saliva microbiota	Baseline, month 3, month 6	Untargeted Metabolomics

Trial Locations

Locations (1)

University of Illinois at Chicago; 🇺🇸 Chicago, Illinois, United States